You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

8 Results
Guidelines and Advice
Status: Current
ID: MOTAC-7
Jan 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
trabectedin (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Drug
Other Name(s): Tecvayli®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Drug
Other Name(s): Tukysa™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Mekinist®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Trecondyv®
Quick Link(s):
Drug Monograph
Jan 2025